Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...
Stocktwits on MSN
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests
The company's obesity drug candidate VK3019 showed stronger early weight-loss signals than Novo Nordisk’s amylin therapy. ・The company said enrollment has been completed across both Phase 3 Vanquish ...
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight ...
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited (“Verdiva” or “the Company”) a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and ...
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
1d
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss
In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million as research and development spending accelerated, while confirming that its Phase 3 VANQUISH-1 and ...
No. 11 / 2026Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight ...
Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study. The highest dose of the weekly injection, ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabete ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Allison DeAngelis is the ...
Please provide your email address to receive an email when new articles are posted on . Petrelintide is a once-weekly amylin analog currently under investigation for the treatment of obesity. The ...
SAN DIEGO (Reuters) - Analysis of an earlier trial found a "clinically insignificant" link between changes in heart rhythms and use of Bydureon, a long-acting diabetes drug being developed by Amylin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results